Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Phase 1

Completed

Conditions: Moderate Asthma
Asthma

Interventions: Drug: REGN3500
Drug: Placebo

First Posted Date: 2016-12-21

Last Posted Date: 2018-12-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT02999711

Locations: 🇬🇧
Regeneron Research Site, Manchester, United Kingdom

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN3500
Drug: Placebo

First Posted Date: 2016-11-08

Last Posted Date: 2017-11-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02958436

Locations: 🇧🇪
Site 1, Ghent, Belgium

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo
Drug: Praluent (Alirocumab)

First Posted Date: 2016-11-08

Last Posted Date: 2021-05-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 2176

Registration Number: NCT02957682

Locations: 🇺🇦
Regeneron Study Site 1, Vinnitsa, Ukraine
🇺🇦
Regeneron Study Site, Vinnitsa, Ukraine
🇺🇦
Regeneron Study Site 2, Vinnitsa, Ukraine

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN1033
Drug: REGN2477
Other: Placebo

First Posted Date: 2016-10-24

Last Posted Date: 2024-08-09

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 82

Registration Number: NCT02943239

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: REGN2477

First Posted Date: 2016-08-17

Last Posted Date: 2017-02-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT02870400

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN2222

First Posted Date: 2016-07-11

Last Posted Date: 2016-11-04

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02828397

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN3470-3471-3479
Drug: Placebo

First Posted Date: 2016-05-19

Last Posted Date: 2018-02-05

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT02777151

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Cutaneous Squamous Cell Carcinoma

Interventions: Drug: cemiplimab

First Posted Date: 2016-05-03

Last Posted Date: 2024-12-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 432

Registration Number: NCT02760498

Locations: 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
University of Arizona Cancer Center, Phoenix, Arizona, United States

and more 75 locations